Ionis Pharmaceuticals, Inc. (IONS)
After hours:
| Previous Close | 37.95 |
| Open | 38.08 |
| Bid | 38.41 x 100 |
| Ask | 38.45 x 100 |
| Day's Range | 37.63 - 38.98 |
| 52 Week Range | 35.95 - 54.44 |
| Volume | |
| Avg. Volume | 1,584,832 |
| Market Cap | 6.062B |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.52 |
| Earnings Date | Oct 31, 2024 - Nov 04, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 61.90 |
Insider MonkeyIonis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
We recently compiled a list of the 10 Stocks with Biggest Upside Potential According to Hedge Funds. In this article, we are going to take a look at where Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stands against the other stocks with biggest upside potential. The US equities saw a strong move after the September jobs report exceeded the economists’ estimates. […]
GlobeNewswireNew Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of nusinersen (50/28 mg) in both individuals previously treated and treatment-naïve to nusinersen Investigational regimen also shows more rapid slowing of neurodegeneration, as measured by neurofilamentBiogen plans to submit regulatory applications around the world for approval of the nusinersen higher dose regimen CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BII
PR NewswireNew positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be presented at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Boston, Massachusetts.
